• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腺癌的ErbB-2/HER2致癌受体:从无人问津到拥有多种基质配体。

The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands.

作者信息

Tzahar E, Yarden Y

机构信息

Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.

出版信息

Biochim Biophys Acta. 1998 Feb 20;1377(1):M25-37. doi: 10.1016/s0304-419x(97)00032-2.

DOI:10.1016/s0304-419x(97)00032-2
PMID:9540810
Abstract

Extensive clinical and biochemical evidence implicates ErbB-2, a transmembrane tyrosine kinase related to growth factor receptors, in the development, metastasis, and resistance to therapy of multiple, common human carcinomas. Previous attempts to uncover an ErbB-2-specific ligand led to isolation of the neuregulin (NRG) family, but these ligands, like all other growth factors with an EGF-like motif, only indirectly active ErbB-2. On the other hand, biochemical and genetic evidence suggest a non-autonomous function of ErbB-2 in an interactive ErbB signaling network. Accordingly, the oncoprotein acts as a shared signaling subunit of primary growth factor receptors. By stabilizing heterodimers with other ErbB proteins, ErbB-2 prolongs and enhances signal transduction by a large group of stroma-derived growth factors. Furthermore, we have proposed a model in which all ErbB-2 ligands are bivalent and bind to ErbB-2 with low affinity, following high affinity binding to a primary receptor with which ErbB-2 is heterodimerized. Thus the presence of ErbB-2 in relevant ErbB heterodimeric structures on the surfaces of certain epithelial tumor cells can amplify signals arising from the binding of stromal ErbB ligands. This effect, in turn, may promote the growth of carcinoma cells.

摘要

大量临床和生化证据表明,与生长因子受体相关的跨膜酪氨酸激酶ErbB-2参与多种常见人类癌症的发生、转移及对治疗的耐药性。以往试图寻找ErbB-2特异性配体的研究导致了神经调节蛋白(NRG)家族的分离,但这些配体与所有其他具有表皮生长因子(EGF)样基序的生长因子一样,只能间接激活ErbB-2。另一方面,生化和遗传学证据表明,ErbB-2在相互作用的ErbB信号网络中具有非自主功能。因此,该癌蛋白作为主要生长因子受体的共享信号亚基。通过与其他ErbB蛋白稳定异二聚体,ErbB-2延长并增强了一大类基质衍生生长因子的信号转导。此外,我们提出了一个模型,其中所有ErbB-2配体都是二价的,在与ErbB-2异二聚化的主要受体高亲和力结合后,以低亲和力与ErbB-2结合。因此,某些上皮肿瘤细胞表面相关ErbB异二聚体结构中存在ErbB-2可以放大基质ErbB配体结合产生的信号。反过来,这种效应可能促进癌细胞的生长。

相似文献

1
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands.腺癌的ErbB-2/HER2致癌受体:从无人问津到拥有多种基质配体。
Biochim Biophys Acta. 1998 Feb 20;1377(1):M25-37. doi: 10.1016/s0304-419x(97)00032-2.
2
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.人类癌症中的ErbB-2/HER2癌蛋白可能仅作为多种基质衍生生长因子的共同共受体发挥作用。
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4995-5000. doi: 10.1073/pnas.96.9.4995.
3
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.ErbB-2是神经分化因子(NDF)和表皮生长因子(EGF)受体的常见辅助亚基:对乳腺癌的影响。
EMBO J. 1996 Jan 15;15(2):254-64.
4
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.生长因子受体的ErbB/HER信号网络的生化及临床意义
Adv Cancer Res. 2000;77:25-79.
5
Biology of HER2 and its importance in breast cancer.HER2的生物学特性及其在乳腺癌中的重要性。
Oncology. 2001;61 Suppl 2:1-13. doi: 10.1159/000055396.
6
ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.表皮生长因子受体与表皮生长因子样配体:通过组合信号传导进行细胞谱系确定和肿瘤发生。
J Mammary Gland Biol Neoplasia. 1997 Apr;2(2):97-107. doi: 10.1023/a:1026343528967.
7
Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase.神经调节蛋白-4:一种通过ErbB-4受体酪氨酸激酶发挥作用的新型生长因子。
Oncogene. 1999 Apr 29;18(17):2681-9. doi: 10.1038/sj.onc.1202631.
8
The ErbB/HER family of protein-tyrosine kinases and cancer.表皮生长因子受体(ErbB)/HER 家族蛋白酪氨酸激酶与癌症。
Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20.
9
Biochemistry of HER2 oncogenesis in breast cancer.
Breast Dis. 2000;11:31-48. doi: 10.3233/bd-1999-11104.
10
Bivalence of EGF-like ligands drives the ErbB signaling network.表皮生长因子样配体的二价性驱动着表皮生长因子受体(ErbB)信号网络。
EMBO J. 1997 Aug 15;16(16):4938-50. doi: 10.1093/emboj/16.16.4938.

引用本文的文献

1
Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor.放射治疗联合双重免疫检查点抑制剂增强 HER2 阳性鼠肿瘤转移模型中的抗肿瘤免疫反应。
Jpn J Radiol. 2022 Dec;40(12):1307-1315. doi: 10.1007/s11604-022-01303-z. Epub 2022 Jun 28.
2
Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies.核因子红细胞2相关因子2在抗癌治疗作用机制及耐药性中的新作用
Cancer Drug Resist. 2019 Sep 19;2(3):490-515. doi: 10.20517/cdr.2019.57. eCollection 2019.
3
HER2 Signaling in Breast Cancer.
乳腺癌中的HER2信号传导
Adv Exp Med Biol. 2021;1187:53-79. doi: 10.1007/978-981-32-9620-6_3.
4
Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer.人表皮生长因子受体2阳性乳腺癌的分子机制与转化治疗
Int J Mol Sci. 2016 Dec 14;17(12):2095. doi: 10.3390/ijms17122095.
5
Prognostic values of four Notch receptor mRNA expression in gastric cancer.四种Notch受体mRNA表达在胃癌中的预后价值
Sci Rep. 2016 Jul 1;6:28044. doi: 10.1038/srep28044.
6
The prognostic roles of ALDH1 isoenzymes in gastric cancer.醛脱氢酶1同工酶在胃癌中的预后作用。
Onco Targets Ther. 2016 Jun 7;9:3405-14. doi: 10.2147/OTT.S102314. eCollection 2016.
7
Prognostic values of Notch receptors in breast cancer.Notch受体在乳腺癌中的预后价值。
Tumour Biol. 2016 Feb;37(2):1871-7. doi: 10.1007/s13277-015-3961-6. Epub 2015 Sep 1.
8
Allelic imbalance at the HER2/TOP2A locus in breast cancer.乳腺癌中HER2/TOP2A基因座的等位基因不平衡。
Diagn Pathol. 2015 May 29;10:56. doi: 10.1186/s13000-015-0289-x.
9
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.多中心 II 期研究:曲妥珠单抗和拉帕替尼联合激素治疗且不联合化疗治疗人表皮生长因子受体 2 过表达乳腺癌患者:TBCRC 006。
J Clin Oncol. 2013 May 10;31(14):1726-31. doi: 10.1200/JCO.2012.44.8027. Epub 2013 Apr 8.
10
Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells.瘦素信号通路在乳腺癌及癌干细胞中的致癌作用与治疗靶点
Biochim Biophys Acta. 2012 Apr;1825(2):207-22. doi: 10.1016/j.bbcan.2012.01.002. Epub 2012 Jan 24.